Scientific Opinion on the substantiation of health claims related to Lactobacillus paracasei LPC 01 (CNCM I-1390) and treatment of disease (ID 3055, further assessment) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

Lactobacillus paracasei LPC 01, health claims
First published in the EFSA Journal
7 August 2012
28 June 2012
Scientific Opinion


Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to provide a scientific opinion on a health claim pursuant to Article 13 of Regulation (EC) No 1924/2006 in the framework of further assessment related to Lactobacillus paracasei LPC 01 (CNCM I-1390) and treatment of disease. The food constituent, L. paracasei LPC 01 (CNCM I-1390), is sufficiently characterised. The claimed effect proposed for further assessment is “relieve symptoms typically associated with Irritable Bowel Syndrome (IBS), especially diarrhoea-predominant IBS, and to help reduce the daily number of bowel movements as well as improve the consistency of faeces in adult subjects reporting acute diarrhoea”. The proposed target population is “adults suffering either from Irritable Bowel Syndrome, especially diarrhoea-predominant IBS, or from acute diarrhoea”. The Panel considers that the claimed effect is related to the treatment of a disease and does not comply with the criteria laid down in Regulation (EC) No 1924/2006.

Panel members at the time of adoption

Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen
Panel on Dietetic Products, Nutrition and Allergies
nda [at]
EFSA Journal 2012;10(8):2850
Question Number
On request from
European Commission